Accelerate discovery
AI that accelerates drug discovery, optimizes clinical trials, and automates regulatory intelligence. GxP-compliant solutions for pharma, biotech, and medical device companies.
From bench to bedside, faster
AI in life sciences and pharmaceutical companies encompasses drug discovery acceleration, clinical trial optimization, pharmacovigilance automation, and regulatory intelligence that reduce time-to-market for new therapies while improving safety signal detection and regulatory submission quality.
Drug development takes 10-15 years and costs $2.6B on average. Clinical trial failures, regulatory complexity, and manual literature review consume resources that could be driving innovation.
Our Life Sciences AI Platform accelerates every phase — from target identification and molecular optimization through trial design, enrollment prediction, and regulatory submission. GxP-compliant by design.
Built for the unique validation requirements of life sciences. Every model is documented to 21 CFR Part 11 standards, every pipeline supports computer system validation, and every insight has full traceability.
AI across the drug lifecycle
From discovery to post-market surveillance — validated AI for every stage.
Drug Discovery AI
Target identification, molecular property prediction, lead optimization, and ADMET forecasting. AI that reduces the discovery timeline by identifying promising candidates faster.
Clinical Trial AI
Protocol optimization, site selection, enrollment prediction, and patient matching. Reduce screen failures, accelerate enrollment, and identify early signals of efficacy or safety.
Real-World Evidence
RWE generation from EHR, claims, and registry data. Support regulatory submissions, payer negotiations, and label expansion with validated real-world outcomes data.
Pharmacovigilance
Automated adverse event detection, signal management, and ICSR processing. NLP for literature monitoring and social media surveillance with regulatory-grade accuracy.
Regulatory Intelligence
Automated regulatory tracking, submission preparation, and compliance monitoring across global jurisdictions. FDA, EMA, and PMDA requirements managed with AI-assisted documentation.
Manufacturing QA
Process analytical technology, batch optimization, and deviation prediction for pharma manufacturing. Ensure quality while maximizing yield and reducing batch failures.
GxP-validated AI delivery
Compliant development methodology for regulated environments.
Validation Planning
Define validation strategy, URS requirements, and risk assessment. Map AI/ML applications to GAMP 5 categories and establish the appropriate level of validation documentation.
Data Foundation
Integrate clinical, genomic, and operational data with full lineage tracking. CDISC-compliant data models, controlled terminologies, and audited transformation pipelines.
Model Development
Develop and train models with complete documentation — IQ/OQ/PQ protocols, performance specifications, and validation test cases. Reproducible from any point in time.
CSV & Deployment
Computer System Validation according to 21 CFR Part 11. Electronic signatures, audit trails, access controls, and change management procedures for production systems.
Lifecycle Management
Ongoing model monitoring, periodic revalidation, and change control processes. Ensure AI systems maintain validated state throughout their operational lifecycle.
Life Sciences AI Impact
Frequently asked questions
AI in life sciences and pharmaceutical companies encompasses drug discovery acceleration, clinical trial optimization, pharmacovigilance automation, and regulatory intelligence. These solutions address target identification, molecular optimization, patient matching, adverse event detection, and submission preparation — all designed for the GxP-validated, compliance-heavy demands of pharma and biotech organizations.
AI accelerates drug discovery through target identification, molecular property prediction, lead optimization, and ADMET forecasting. Machine learning models analyze vast chemical libraries and biological data to identify promising candidates faster, reducing the discovery timeline from years to months while improving the probability of clinical success.
AI-powered pharmacovigilance uses natural language processing for automated adverse event detection, signal management, and ICSR processing. NLP models monitor scientific literature, social media, and case reports with regulatory-grade accuracy, enabling faster safety signal identification while reducing manual case processing workloads by up to 60%.
AI optimizes clinical trials through protocol optimization, site selection, enrollment prediction, and patient matching. Machine learning reduces screen failures, accelerates enrollment timelines by up to 40%, and identifies early signals of efficacy or safety — enabling faster go/no-go decisions and reducing overall trial costs significantly.
Deploying AI in a pharma company follows a GxP-validated methodology: validation planning, data foundation, model development, CSV and deployment, and lifecycle management. Timelines vary by use case, but pharmacovigilance automation pilots can be operational in 8–12 weeks, while full clinical trial optimization platforms may take 4–6 months including computer system validation.
Ready to accelerate your pipeline?
GxP-compliant AI solutions that accelerate drug development, optimize clinical operations, and strengthen regulatory submissions.